New Lung Cancer Drug Could Double Progression Survival
A new treatment may help adults with lung cancer who have previously been treated with EGFR inhibitors.
Updated on Oct. 27, 2026 in Cancer
Live Poll
Do you trust that pharmaceutical partnerships to develop new drugs reliably prioritize patient outcomes?
Bristol Myers Squibb has reported positive results from a Phase 3 trial of the cancer drug izalontamab brengitecan in patients with non-small cell lung cancer. The drug achieved a median progression-free survival of 11.1 months, marking a notable improvement for this patient population.
Why it matters
This development represents a potential new treatment path for patients who have already been treated with EGFR tyrosine kinase inhibitors. As data for overall survival remain immature and regulatory approval is years away, these findings provide early evidence of the drug's potential efficacy in solid tumors.
In a head-to-head Phase 3 trial conducted in mainland China, izalontamab brengitecan demonstrated a median progression-free survival of 11.1 months compared to 5.7 months for platinum-based chemotherapy among non-small cell lung cancer patients. Data for overall survival remain immature.
The players
Bristol Myers Squibb
A pharmaceutical company focused on the development of innovative medicines for serious diseases including oncology.
Sichuan Biokin Pharmaceutical
A pharmaceutical company that managed the clinical trial testing for the new cancer treatment.
SystImmune
A biotechnology company that entered into an exclusive licensing and collaboration agreement with Bristol Myers Squibb.
The details
The drug works as a targeted therapy being tested in patients who have previously been treated with an EGFR tyrosine kinase inhibitor. By comparing the drug directly against traditional platinum-based chemotherapy, researchers aimed to determine if this new candidate offers better control over tumor progression. This trial marks the fifth solid tumor type in which the drug has shown potential efficacy in clinical studies.
Timeline
December 2023: Bristol Myers Squibb announced a licensing agreement for the drug.
October 26, 2026: Bristol Myers Squibb announced the Phase 3 trial results.
Health Landscape
This development adds to the ongoing search for effective second-line therapies for patients with non-small cell lung cancer who have already progressed on standard EGFR inhibitors. It builds on the existing research landscape where pharmaceutical companies are actively testing new candidates to improve long-term outcomes.
Patients currently managing non-small cell lung cancer should discuss their treatment history with their physician to understand if new trials or emerging therapies might be relevant to their specific EGFR mutation status. It is important to note that this specific drug is currently in clinical testing and is not yet available for general clinical use.
The takeaway
While these early Phase 3 results suggest potential for a new treatment option, regulatory approval remains years away for this drug. Readers interested in the latest clinical advancements in lung cancer care should maintain ongoing conversations with their oncology team about current clinical trial opportunities.
Further reading
For more information on the current state of lung cancer treatments, visit Cancer.
Source note: This article includes information reported by The Motley Fool.
Live Poll
Do you trust that pharmaceutical partnerships to develop new drugs reliably prioritize patient outcomes?
